治疗偏好在低风险的乳头甲状腺小癌:一个离散选择实验的治疗偏好
Siming Wang1, Jialiang Feng2, Jinfeng Yue1
1The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.
Frontiers in public health
|December 31, 2025
概括
新诊断的低风险乳头甲状腺微癌患者在治疗决策中优先考虑疾病复发风险,而不是其他因素. 了解这些偏好是改善以患者为中心的护理和避免过度治疗的关键.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
- 医疗保健服务研究 医疗服务研究
背景情况:
- 乳头甲状腺微瘤 (PTMC) 是一种常见的甲状腺癌,通常被认为是低风险的.
- 对PTMC的治疗决定涉及复杂的权衡,影响患者的选择.
- 了解患者的偏好对于个性化治疗策略至关重要.
研究的目的:
- 评估新诊断的低风险PTMC患者的治疗偏好.
- 分析患者在不同PTMC治疗方案之间进行选择时所做出的权衡.
- 确定影响PTMC管理中的患者决策的关键属性.
主要方法:
- 使用离散选择实验的横截面研究设计.
- 参与者根据七个属性评估了治疗选择,包括复发风险和成本.
- 混合逻辑模型用于分析偏好和支付意愿.
主要成果:
- 疾病复发或进展的10年风险是最重要的因素 (RI=58.4%).
- 患者更喜欢热除而不是开放手术;积极监测是最不喜欢的.
- 社会人口统计学和心理因素也影响了治疗偏好.
结论:
- 医疗保健提供者应该清楚地传达长期影响,以促进知情的PTMC治疗决策.
- 提高以患者为中心的护理,健康教育和解决过度治疗是必不可少的.
- 患者的偏好在很大程度上决定了在治疗低风险的甲状腺 papillary microcarcinoma 的选择.
相关概念视频
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...


